Last reviewed · How we verify
sibutramine+ microcrystalline cellulose
Sibutramine inhibits the reuptake of norepinephrine, serotonin, and dopamine in the central nervous system, increasing satiety and reducing appetite.
Sibutramine inhibits the reuptake of norepinephrine, serotonin, and dopamine in the central nervous system, increasing satiety and reducing appetite. Used for Obesity management in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with comorbidities.
At a glance
| Generic name | sibutramine+ microcrystalline cellulose |
|---|---|
| Also known as | Reduxin® |
| Sponsor | Promomed, LLC |
| Drug class | Sympathomimetic amine; appetite suppressant |
| Target | Norepinephrine transporter (NET), serotonin transporter (SERT), dopamine transporter (DAT) |
| Modality | Small molecule |
| Therapeutic area | Obesity; Weight management |
| Phase | FDA-approved |
Mechanism of action
Sibutramine is a sympathomimetic amine that acts as a norepinephrine-serotonin-dopamine reuptake inhibitor. By blocking the reuptake of these neurotransmitters at presynaptic terminals, it increases their synaptic concentration, leading to enhanced satiety signals and decreased food intake. Microcrystalline cellulose is an inert pharmaceutical excipient used as a bulking agent and filler in the formulation.
Approved indications
- Obesity management in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with comorbidities
Common side effects
- Dry mouth
- Insomnia
- Headache
- Constipation
- Increased heart rate
- Increased blood pressure
- Anxiety
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sibutramine+ microcrystalline cellulose CI brief — competitive landscape report
- sibutramine+ microcrystalline cellulose updates RSS · CI watch RSS
- Promomed, LLC portfolio CI